MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Trims Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. reduced its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 1.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 238,328 shares of the biotechnology company’s stock after selling 4,374 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned about 0.17% of Arrowhead Pharmaceuticals worth $3,046,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Exchange Traded Concepts LLC grew its holdings in Arrowhead Pharmaceuticals by 31.8% during the 1st quarter. Exchange Traded Concepts LLC now owns 49,247 shares of the biotechnology company’s stock valued at $627,000 after buying an additional 11,879 shares in the last quarter. Hsbc Holdings PLC bought a new position in shares of Arrowhead Pharmaceuticals during the 1st quarter valued at approximately $173,000. GAMMA Investing LLC boosted its position in shares of Arrowhead Pharmaceuticals by 297.6% during the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 1,628 shares during the last quarter. New York State Teachers Retirement System boosted its position in shares of Arrowhead Pharmaceuticals by 6.9% during the 1st quarter. New York State Teachers Retirement System now owns 148,376 shares of the biotechnology company’s stock valued at $1,890,000 after acquiring an additional 9,593 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its position in shares of Arrowhead Pharmaceuticals by 117.8% during the 1st quarter. Principal Financial Group Inc. now owns 629,075 shares of the biotechnology company’s stock valued at $8,014,000 after acquiring an additional 340,191 shares during the last quarter. 62.61% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 15,000 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $25.00, for a total value of $375,000.00. Following the transaction, the insider owned 247,122 shares in the company, valued at $6,178,050. The trade was a 5.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 25,000 shares of company stock valued at $575,000 in the last 90 days. 4.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Wall Street Zen downgraded Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, July 18th. HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, September 2nd. B. Riley upgraded Arrowhead Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 11th. Chardan Capital reiterated a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 11th. Finally, TD Cowen upgraded Arrowhead Pharmaceuticals to a “strong-buy” rating in a research report on Monday, July 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $43.14.

Arrowhead Pharmaceuticals Stock Performance

Shares of Arrowhead Pharmaceuticals stock opened at $29.72 on Friday. The firm has a market cap of $4.11 billion, a P/E ratio of -23.22 and a beta of 1.00. The company has a current ratio of 4.87, a quick ratio of 4.87 and a debt-to-equity ratio of 0.39. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $9.57 and a 12 month high of $31.13. The stock’s fifty day moving average price is $19.99 and its 200-day moving average price is $16.55.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The firm had revenue of $27.77 million during the quarter, compared to analysts’ expectations of $29.01 million. During the same quarter in the prior year, the company posted ($1.38) EPS. On average, equities research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.